Teacher Retirement System of Texas Grows Position in Cogent Biosciences, Inc. (NASDAQ:COGT)

Teacher Retirement System of Texas increased its position in Cogent Biosciences, Inc. (NASDAQ:COGT) by 15.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,983 shares of the technology company’s stock after purchasing an additional 2,396 shares during the period. Teacher Retirement System of Texas’ holdings in Cogent Biosciences were worth $140,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Cogent Biosciences by 8.1% during the third quarter. FMR LLC now owns 8,319,411 shares of the technology company’s stock valued at $89,850,000 after purchasing an additional 625,743 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Cogent Biosciences by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,280,793 shares of the technology company’s stock worth $24,638,000 after buying an additional 300,062 shares during the last quarter. SG Americas Securities LLC increased its position in Cogent Biosciences by 2,865.3% during the 4th quarter. SG Americas Securities LLC now owns 964,712 shares of the technology company’s stock valued at $7,525,000 after buying an additional 932,179 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Cogent Biosciences by 0.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 833,155 shares of the technology company’s stock valued at $6,499,000 after buying an additional 7,362 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Cogent Biosciences by 8.0% in the third quarter. Wellington Management Group LLP now owns 342,323 shares of the technology company’s stock worth $3,697,000 after acquiring an additional 25,470 shares in the last quarter.

Analyst Upgrades and Downgrades

COGT has been the subject of several recent analyst reports. HC Wainwright lowered their price target on Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Robert W. Baird reduced their price objective on shares of Cogent Biosciences from $10.00 to $8.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. Scotiabank assumed coverage on shares of Cogent Biosciences in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $17.00 target price on the stock. Needham & Company LLC reissued a “hold” rating on shares of Cogent Biosciences in a research report on Wednesday, February 26th. Finally, Wedbush restated a “neutral” rating and issued a $11.00 price objective on shares of Cogent Biosciences in a report on Tuesday, February 25th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Cogent Biosciences presently has an average rating of “Moderate Buy” and an average target price of $14.43.

Cogent Biosciences Stock Down 1.2 %

COGT opened at $5.72 on Thursday. Cogent Biosciences, Inc. has a twelve month low of $5.48 and a twelve month high of $12.61. The firm has a 50 day moving average price of $7.73 and a 200-day moving average price of $9.01. The stock has a market capitalization of $651.22 million, a price-to-earnings ratio of -2.31 and a beta of 1.67.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.